Physician profile
Mark T Weaver
NPI 1508968926
$620.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $15.67 · 2022: $70.08 · 2023: $25.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $172.17 | 2019 | |
| Mylan Specialty L.P. | $148.96 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $82.76 | 2019 | |
| Insmed, INC. | $63.64 | 2019-2020 | |
| Csl Behring | $56.28 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $25.87 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.97 | 2022 | |
| Gilead Sciences, INC. | $17.25 | 2019 | |
| Genentech USA, INC. | $16.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.